IO Biotech expands collaboration with MSD – begins phase II trial

IO Biotech is initiating a third clinical collaboration with partner MSD to develop a combination treatment for three types of cancer, comprised of MSD's blockbuster drug Keytruda and IO Biotech's lead candidate. A phase II trial is on its way, and should it prove successful, IO Biotech will maintain global commercial rights.
Mai-Britt Zocca, CEO and founder of IO Biotech, has signed off on the Danish cancer company's third deal with US-based MSD | Photo: IO Biotech / PR
Mai-Britt Zocca, CEO and founder of IO Biotech, has signed off on the Danish cancer company's third deal with US-based MSD | Photo: IO Biotech / PR
by albert rønning-andersson, translated by daniel pedersen

Danish cancer company IO Biotech is entering its third clinical collaboration with US-based pharmaceutical giant MSD. The ambition is to develop a drug for the treatment of three different types of cancer, it reports in a press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading